Archive: Company News
Company News: Curetis Partners with Biotest to support academic PEPPER Pentaglobin® Peritonitis Trial with Unyvero IAI Application
— Trial sponsored by University Clinic RWTH Aachen investigates personalized treatment approaches with Biotest’s Pentaglobin® in peritonitis patients
— Curetis to provide testing services for different samples from up to 200 patients with its recently launched Unyvero IAI Application for intra-abdominal infections
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has closed a partnership with Biotest AG (Dreieich, Germany). Under the terms of the agreement, Curetis will provide Biotest with in-house testing services using Curetis’ Unyvero IAI cartridge for the diagnosis of intra-abdominal infections. Financial terms were not disclosed.
Company News: Curetis to Report its Half-Year Results 2017 on August 16, 2017
– Company will host earnings conference call and webcast
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it will publish its financial results for the first six months ended on June 30, 2017, on August 16, 2017. In addition, the Company will host a public earnings conference call and webcast on August 16, 2017, at 03:00 pm CET / 09:00 am EST to present the H1 2017 financial results, highlight the most important events and provide an outlook for the second half of 2017 and beyond.
Company News: Agena Bioscience and Intermountain Healthcare Announce Research Collaboration To Advance Precision Medicine
Agena Bioscience and Intermountain Healthcare announced today a strategic collaboration that focuses on expanding the use of Agena’s MassARRAY® System in oncology applications. The collaboration concentrates on expansion of Agena’s technology with the goal of focused panels for liquid and tissue biopsy. The molecular tests augment laboratory services available worldwide from Intermountain Precision Genomics to advance precision medicine in cancer.
Company News: Phenex AG announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I
– Phenex drug discovery has now resulted in two clinical stage programs this year through research collaborations
Phenex Pharmaceuticals AG (Phenex) today announced the achievement of a milestone in the collaboration with Janssen Biotech, Inc. (Janssen), which triggers a 6M US$ payment by Janssen. The milestone payment relates to a R&D collaboration between Phenex and Janssen, with a total potential value of 135 M USD, initiated in late 2012, to jointly discover RORgt inhibitors for the treatment of chronic inflammatory and autoimmune diseases.